Zacks Research Has Optimistic Outlook of BIO Q2 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Research analysts at Zacks Research raised their Q2 2026 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Thursday, July 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.46 per share for the quarter, up from their prior forecast of $2.45. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2027 earnings at $1.95 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The company's revenue was down 4.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.30 earnings per share.

Several other equities analysts have also commented on BIO. Wells Fargo & Company dropped their price target on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research report on Monday, June 9th. Royal Bank Of Canada dropped their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday. Finally, UBS Group decreased their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $324.25.

Bio-Rad Laboratories Trading Up 1.1%

Shares of NYSE:BIO traded up $2.61 during trading on Monday, reaching $249.87. The stock had a trading volume of 174,517 shares, compared to its average volume of 297,862. Bio-Rad Laboratories has a fifty-two week low of $211.43 and a fifty-two week high of $387.99. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average price of $238.15 and a 200-day moving average price of $267.35. The stock has a market cap of $6.80 billion, a P/E ratio of -3.28 and a beta of 0.95.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio raised its holdings in shares of Bio-Rad Laboratories by 3.6% during the second quarter. Public Employees Retirement System of Ohio now owns 6,307 shares of the medical research company's stock worth $1,522,000 after purchasing an additional 218 shares during the period. GAMMA Investing LLC raised its holdings in shares of Bio-Rad Laboratories by 20.9% during the second quarter. GAMMA Investing LLC now owns 734 shares of the medical research company's stock worth $177,000 after purchasing an additional 127 shares during the period. UMB Bank n.a. raised its holdings in shares of Bio-Rad Laboratories by 89.8% during the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company's stock worth $40,000 after purchasing an additional 79 shares during the period. Exchange Traded Concepts LLC raised its holdings in shares of Bio-Rad Laboratories by 123.4% during the second quarter. Exchange Traded Concepts LLC now owns 13,932 shares of the medical research company's stock worth $3,362,000 after purchasing an additional 7,697 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth $238,000. 65.24% of the stock is owned by institutional investors and hedge funds.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.